Emergent's Pending Acquisition "Evolutionary Biologics" Engages "Aesthetics By Design" to Market, Sell and Distribute Regenerative Medicine Products Produced by Evolutionary Biologics with the Initial Focus Being Exo Elixir(TM)

Rhea-AI Summary

Emergent Health Corp. (OTC PINK:EMGE) announces its acquisition of Evolutionary Biologics, specializing in regenerative biological products. The partnership with By Design Medical aims to commercially launch their flagship product, Exo Elixir TM, a regenerative serum derived from dermal fibroblast stem cells. The biologics market is projected to grow from US $366.43 billion in 2021 to over US $719.84 billion by 2030. The acquisition is expected to finalize within two weeks, enhancing Emergent's market position in aesthetics and regenerative medicine.

Positive

• Acquisition of Evolutionary Biologics potentially strengthens Emergent's product offerings in regenerative medicine.
• Collaborative marketing with By Design Medical expected to drive revenue growth through effective sales strategies.
• The biologics market is experiencing significant growth, providing a favorable environment for Emergent's new product line.

Negative

• The reliance on sales representatives for revenue generation poses risks if recruitment or performance targets are not met.
• Integration challenges may arise post-acquisition, potentially affecting operational efficiency.

HAUPPAUGE, NY / ACCESSWIRE / July 26, 2022 / Emergent Health Corp. ("Emergent") (OTC PINK:EMGE) announces its pending Acquisition Evolutionary Biologics, Inc., (Evolutionary Biologics), a market leading innovator of regenerative biological products using science and technology to build products creating external beauty engages By Design Medical, a DBA of Aesthetics By Design to market, sell and distribute Regenerative Medicine Products produced by Evolutionary Biologics. The initial focus shall be Exo Elixir ^TM, a sub-dermal regenerative serum derived from dermal fibroblast stem cells (does not contain any live cells) with a proprietary mixture of growth factors, cytokines, collagen, and soluble matrix proteins ideal for skin cells to regenerate themselves to the Aesthetic Trade.

The global biologics market size was valued at US $366.43 billion in 2021 and it is expected to hit over US$ 719.84 billion by 2030 with a noteworthy CAGR of 7.8% from 2022 to 2030. A biologic medication is a product that is made from live organisms and contains living organism components. Recombinant protein, tissues, allergens, genes, cells, blood components, blood, and vaccinations are all examples of biologics. Anemia, hemophilia, chronic migraine, hepatitis B, rheumatoid arthritis, inflammatory bowel disease, and other disorders and infections are treated with biologics. Various government efforts, higher share of biologics in the market, and rising use of biopharmaceuticals over chemically produced molecules, and many other factors are driving the biologics market expansion in the forecast period.

Tamara Paul, CEO of By Design Medical, a DBA of Aesthetics By Design stated "Aesthetics By Design is pleased to begin the collaboration with Evolutionary Biologics. Together our companies will change the landscape of regenerative medicine and launch revolutionary innovated products into the aesthetics market."

Jim Morrison, President and CEO of Evolutionary Biologics stated "Tamara has recruited, trained, and managed over 700 sales reps, who have generated millions of dollars in sales in the medical sales channel. She expects to have 8 to 10 reps in the field in August with a target of 75 generating $200,000 per month in Revenues by year-end."

The acquisition of Evolutionary Biologics by Emergent Health is expected to close within the next two weeks.

James W. Zimbler, CEO of Emergent stated, "We're extremely pleased and proud to have Tamara and the entire By Design Medical team part of the roll out of Evolutionary Biologics many wonderful products and are hopeful By Design Medical will represent all of Emergent Health's family of products."

ABOUT EMERGENT HEALTH CORPORATION

Emergent is developing a line of products in the field of Regenerative Medicine and improved neutraceuticals and phytonutritionals available to the general public without a prescription. Its products comprise of ingestibles as well as topicals for the whole family. The company distributes its products online and through Content Based Shopping using Influencers to position products in their produced content throughout the United States and Internationally. PharmaZu, its newly acquired subsidiary, is a pure play, e-commerce products and service provider focused on The Pet Community, Pet Pharmacy and Wellness using Influencers and their content, including the pet pharmacy, vet telehealth and pet wellness businesses. Emergent does not claim any of its products are approved by the FDA to diagnose, treat, cure or prevent any disease.

Before using any products, you should always consult with your Veterinarian and Family Doctor.

SAFE HARBOR STATEMENT

This press release contains forward-looking statements that can be identified by terminology such as "believes," "expects," "potential," "plans," "suggests," "may," "should," "could," "intends," or similar expressions. Many forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results implied by such statements. These factors include, but are not limited to, our ability to continue to enhance our products and systems to address industry changes, our ability to expand our customer base and retain existing customers, our ability to effectively compete in our market segment, the lack of public information on our company, our ability to raise sufficient capital to fund our business, operations, our ability to continue as a going concern, and a limited public market for our common stock, among other risks. Many factors are difficult to predict accurately and are generally beyond the company's control. Forward-looking statements speak only as to the date they are made, and we do not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.

FOR MORE INFORMATION, PLEASE CONTACT:

James Zimbler, CEO
jzimbler@emergenthealthcompany.com
631-806-1420
https://emergenthealthcompany.com/

SOURCE: Emergent Health Corp.

View source version on accesswire.com:
https://www.accesswire.com/709767/Emergents-Pending-Acquisition-Evolutionary-Biologics-Engages-Aesthetics-By-Design-to-Market-Sell-and-Distribute-Regenerative-Medicine-Products-Produced-by-Evolutionary-Biologics-with-the-Initial-Focus-Being-Exo-ElixirTM

FAQ

What is the purpose of Emergent Health's acquisition of Evolutionary Biologics?

The acquisition aims to enhance Emergent's offerings in regenerative medicine and capitalize on the growing biologics market.

What is the expected impact of the acquisition on Emergent's product line?

Emergent expects to introduce innovative products like Exo Elixir to the aesthetics market, potentially increasing revenue.

When is the acquisition of Evolutionary Biologics expected to close?

The acquisition is anticipated to close within two weeks from the announcement on July 26, 2022.

How does the growing biologics market affect Emergent Health?

The biologics market, projected to grow significantly, provides a favorable backdrop for Emergent Health's expanded product offerings.

What are the growth targets for By Design Medical's sales?

By Design Medical aims to have 8 to 10 sales representatives generating approximately $200,000 per month by year-end.